
浏览全部资源
扫码关注微信
遵义市第一人民医院妇产科
纸质出版日期:2019,
扫 描 看 全 文
[1]刘茂永,黄露,龚乾涛,王丹,简远丽,罗丽娜.GnRH-a联合曼月乐对子宫腺肌病患者卵巢功能、子宫体积的影响[J].保健医学研究与实践,2019,16(02):47-50.
Liu Maoyong, Huang Lu, Gong Qiantao, et al. Effects of GnRH-a combined with mirena on ovarian function and uterine volume in patients with adenomyosis[J]. Health Medicine Research and Practice, 2019,16(2):47-50.
[1]刘茂永,黄露,龚乾涛,王丹,简远丽,罗丽娜.GnRH-a联合曼月乐对子宫腺肌病患者卵巢功能、子宫体积的影响[J].保健医学研究与实践,2019,16(02):47-50. DOI:
Liu Maoyong, Huang Lu, Gong Qiantao, et al. Effects of GnRH-a combined with mirena on ovarian function and uterine volume in patients with adenomyosis[J]. Health Medicine Research and Practice, 2019,16(2):47-50. DOI:
目的探讨促性腺激素释放激素激动剂(GnRH-a)联合曼月乐对子宫腺肌病患者卵巢功能、子宫体积的影响。方法本研究选取遵义市某医院2015年2月-2017年6月诊治的74例子宫腺肌病患者为研究对象
采用随机数字表法将患者分为对照组(n=37)与观察组(n=37)。2组患者均于月经周期第3天接受皮下注射GnRHa治疗。第4次注射GnRH-a后
于观察组患者子宫内放置曼月乐。治疗6个月时
比较2组患者的治疗效果及子宫体积;比较2组患者治疗前及治疗6个月时促黄体生成素(LH)、雌二醇(E2)、促卵泡激素(FSH)水平及卵巢间质动脉收缩期峰值(PSV)。结果观察组患者治疗总有效率为97.30%
高于对照组的81.08%
差异有统计学意义(P<0.05)。治疗前
2组患者FSH
LH
E2水平及PSV
子宫体积比较
差异无统计学意义(P>0.05);治疗6个月时
观察组、对照组患者FSH水平分别为(11.25±2.74) U/L及(7.72±1.11) U/L
均高于治疗前
且观察组患者高于对照组
差异有统计学意义(P<0.05);治疗6个月时
观察组、对照组患者PSV分别为(0.054±0.012)m/s及(0.075±0.016) m/s
均低于治疗前
且观察组患者低于对照组
差异有统计学意义(P<0.05);治疗6个月时
观察组、对照组患者子宫体积分别为(101.23±12.47) cm3及(214.52±18.41) cm3
均小于治疗前
且观察组患者小于对照组
差异有统计学意义(P<0.05)。结论 GnRH-a联合曼月乐治疗子宫腺肌病的疗效确切
其可调节卵巢功能
缩小子宫体积
同时提高治疗效果
临床效果显著
值得推广应用。
Objective To investigate the effects of gonadotropin releasing hormone agonist(GnRH-a) combined with Mirena on ovarian function and uterine volume in patients with adenomyosis.Methods Seventy-four patients with adenomyosis who were treated at a Zunyi hospital between February 2015 and June 2017 were included in this study.Based on the use of a random number table
these patients were divided into the trial group(n = 37) or the control group(n =37).All patients received subcutaneous injection of GnRH-a on the third day of menstruation;and intrauterine Mirena placement was performed after the 4 thGnRHa injection for patients in the trial group.At 6 months
treatment response was compared between the two groups.Besides
luteinizing hormone(LH)
estradiol(E2)
follicle-stimulating hormone(FSH)
ovarian stromal artery peak systolic velocity(PSV)
and uterine volume at baseline and at 6 months were also compared between the two groups.Results The overall response rate in the trial group was significantly higher than that in the control group(97.30% vs.81.08%
P<0.05).At baseline
the FSH
LH
E2
PSV
and uterine volume were similar between the two groups(P>0.05).The FSH level was increased compared with baseline in both groups
greater increase in the trial group(11.25±2.74 vs.7.72±1.11 U/L
P<0.05);the PSV was lower than that at baseline in both groups
with a significantly greater reduction in the trial group(0.054±0.012 vs.0.075±0.016 m/s
P<0.05);the uterine volume was smaller than that at baseline in both groups
also with a significantly greater reduction in the trial group(101.23±12.47 vs.214.52±18.41 cm3
P<0.05).Conclusion GnRH-a combined with Mirena has favorable efficacy in treating adenomyosis
which is effective in regulating ovarian function and reducing uterine volume.This combination therapy deserves widespread clinical application.
GnRH-a曼月乐子宫腺肌病卵巢功能
GnRH-aMirenaadenomyosisOvarian function
0
浏览量
49
下载量
8
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621